Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations

Cancer Cell(2021)10.1016/j.ccell.2021.12.004Source: DataRank Database

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations is a research paper published in Cancer Cell (2021). On theSindex it has a DataRank of 0.849. It has been cited 287 times.

N/A

0.849DataRank · unranked

Scored on demand from live citation data

Open Access287 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 14.66)OA: hybridTopics (31)Linked Datasets (22)DataCite Reuse (22)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.849

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (3)

Patrick Bhola ORCID,Alana L. Welm ORCID,Anthony Letai ORCID

Live enrichment

PubMed:34951956 PMC:PMC8752507 OpenAlex:https://openalex.org/W4200579603

National Cancer Institute

Grant: R35CA242427

National Cancer Institute

Grant: U54CA224076

University of Utah

National Institutes of Health

Dana-Farber Cancer Institute

FWCI

14.66

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ccell.2021.12.004

publisherhttps://doi.org/10.1016/j.ccell.2021.12.004

publisherhttps://api.elsevier.com/content/article/PII:S1535610821006164?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610821006164?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34951956

Fields of Study

Cancer Genomics and DiagnosticsProtein Degradation and InhibitorsCAR-T cell therapy researchBiomarkers, TumorHumansMedical OncologyMutationNeoplasmsPharmaceutical PreparationsPrecision Medicine

MeSH Terms

Pharmaceutical PreparationsHumansMedical OncologyMutationNeoplasmsBiomarkers, TumorPrecision Medicine

Keywords

Precision medicinePrecision oncologyPersonalized medicineMedicineClinical trialComputational biologyComputer scienceBioinformaticsOncologyInternal medicineBiologyPathologyPatient-derived ModelsFunctional Precision Medicine

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study

10.6084/m9.figshare.22767471.v1figshare

10.6084/m9.figshare.22767471figshare

Additional file 2 of Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

10.6084/m9.figshare.24264744.v1figshare

Additional file 2 of Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

10.6084/m9.figshare.24264744figshare

Additional file 2 of Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer

10.6084/m9.figshare.24439456.v1figshare

Additional file 2 of Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer

10.6084/m9.figshare.24439456figshare

Additional file 1 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.25459504.v1figshare

Additional file 1 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.25459504figshare

Additional file 2 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.25459654.v1figshare

Additional file 2 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.25459654figshare

Additional file 3 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696256.v1figshare

Additional file 3 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696256figshare

Additional file 4 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696259.v1figshare

Additional file 4 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696259figshare

Additional file 5 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696262.v1figshare

Additional file 5 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696262figshare

Additional file 6 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696265.v1figshare

Additional file 6 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696265figshare

Additional file 7 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696268.v1figshare

Additional file 7 of CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

10.6084/m9.figshare.26696268figshare

Related Papers (10)

Highly accurate protein structure prediction with AlphaFold

N/A

1.6DataRank · unranked

Nature(2021)

co-cited

10.1038/s41586-021-03819-2

Dexamethasone in Hospitalized Patients with Covid-19

N/A

1.4DataRank · unranked

New England Journal of Medicine(2021)

co-cited

10.1056/nejmoa2021436

The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets

Top 3%

6.6DataRank

Nucleic Acids Research(2020)

co-cited

10.1093/nar/gkaa1074

Remdesivir for the Treatment of Covid-19 — Final Report

N/A

12.3DataRank · unranked

New England Journal of Medicine(2020)

co-cited

10.1056/nejmoa2007764

The repertoire of mutational signatures in human cancer

N/A

10.7DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-1943-3

Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

N/A

1.2DataRank · unranked

BMJ(2020)

co-cited

10.1136/bmj.m1328

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

N/A

1.1DataRank · unranked

Cell Discovery(2020)

co-cited

10.1038/s41421-020-0153-3

Discovering the anticancer potential of non-oncology drugs by systematic viability profiling

N/A

5.5DataRank · unranked

Nature Cancer(2020)

co-cited

10.1038/s43018-019-0018-6

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

Top 4%

4.9DataRank

Nature Genetics(2020)

co-cited

10.1038/s41588-020-0603-8

Synergistic and Antagonistic Drug Combinations against SARS-CoV-2

N/A

0.728DataRank · unranked

Molecular Therapy(2020)

co-cited

10.1016/j.ymthe.2020.12.016

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations

FAIR Checklist

DataRank Breakdown

Authors (3)

Funding (5 grants)

Impact

Open Access

Topics

Linked Datasets (22)

Annotations (Europe PMC)

Related Papers (10)